Cecily May Barber
Mishka Terplan- 1Grayken Center for Addiction, Boston Medical Center, Boston, MA, United States
- 2Department of Obstetrics and Gynecology, Boston University School of Medicine and Boston Medical Center, Boston, MA, United States
- 3Friends Research Institute, Baltimore, MD, United States
- 4Department of Family and Community Medicine, University of California, San Francisco, CA, United States
Substance use in pregnant and parenting persons is common, yet still underdiagnosed. Substance use disorder (SUD) is one of the most stigmatized and undertreated chronic medical conditions, and this is exacerbated in the perinatal period. Many providers are not sufficiently trained in screening or treatment for substance use, so gaps in care for this population persist. Punitive policies towards substance use in pregnancy have proliferated, lead to decreased prenatal care, do not improve birth outcomes, and disproportionately impact Black, Indigenous, and other families of color. We discuss the importance of understanding the unique barriers of pregnancy-capable persons and drug overdose as one of the leading causes of maternal death in the United States. We highlight the principles of care from the obstetrician-gynecologist perspective including care for the dyad, person-centered language, and current medical terminology. We then review treatment of the most common substances, discuss SUD during the birthing hospitalization, and highlight the high risk of mortality in the postpartum period.
Introduction
Substance use in pregnant and parenting persons is common, yet both underdiagnosed and undertreated in part due to misunderstanding and misinformation regarding substance use, misuse, and use disorder in pregnancy (1).
Most people in the US use drugs (opioids, alcohol, nicotine/tobacco, stimulants, and cannabis) to which some people develop an addiction, including people who are capable of pregnancy (2). Most people quit or cut back substance use when they become pregnant (3, 4). However, those who continue to use, likely have a substance use disorder (SUD) (5). Addiction, or SUD, is a chronic and treatable medical condition (6). Untreated SUD is associated with preterm delivery, low birth weight, and other negative birth outcomes. In contrast, people with treated addiction are more likely to deliver a normal weight infant at term (7). The old adage “healthy mother equals healthy baby” applies to addiction as it does to other chronic diseases in pregnancy.
Universal assessment of behavioral health is recommended in prenatal care (8–14); however, it is unevenly actualized and some providers and health systems deploy drug testing in place of proper screening (15, 16). Although the effectiveness of treatment in pregnancy is well established, most pregnant people receive no addiction treatment and treatment (including medication) is inequitably distributed across populations (17, 18). In short, the field of addiction medicine as it concerns pregnancy and parenting suffers not from gaps in scientific knowledge, as much as it suffers from gaps in implementation. We know how to care for pregnant and parenting people with SUD. Many of the principles of care were first described almost 50 years ago (19, 20).
Pregnancy and postpartum are a period of significant change both biologically and socially and can lead to new or increased contact with healthcare providers. In this role, all providers have an obligation to present information, resources and support that strengthen this family unit. The complexity of the social and historical context in which people who use substances interact with the healthcare system is highlighted during the perinatal period (21)—most notably, this population faces unique threats of legal repercussions for reporting use and seeking treatment (22). This threat and stigma can lead to significant trauma for pregnant and postpartum persons and disproportionately affects non-White families (23).
This manuscript reviews the principles of care of pregnant and parenting people with SUD from the obstetrician gynecologist perspective. The authors are both obstetrician gynecologists and addiction medicine providers with combined almost three decades of clinical experience. The discussion is centered on the dyad—on the indivisible connection between a pregnant person and the fetus (the “maternal-fetal unit”) and, following birth, the connection between a new mother and an infant—and grounded in both foundational texts as well as contemporary data.
Principles and context
Health care should be both evidence-based and person-centered. Pregnant people with SUD experience discrimination, are denied dignity and respect, and often lack access to evidence-based care (24). Pregnant people with SUD often have a significant history of trauma, including childhood physical or sexual abuse and current intimate partner violence (25–27). Many have interacted with the child welfare system in the past and the potential of child welfare involvement postpartum looms over the entire perinatal period (28, 29). Finally, the birth experience can be traumatizing which can reaffirm existing medical mistrust (30).
To address discrimination and structural inequities, to reflect evidence-based practice, and to actualize person-centered care, attention should focus first on language.
Language is important. The words we use can convey (intentionally or unintentionally) stigma and prejudice (31, 32). Creating a non-judgmental environment is important to provide appropriate care for persons with substance use disorder. Therefore, providers need to model language that is both evidence-based (i.e., clinically accurate) and person-centered (i.e., non-stigmatizing). Providers should avoid slang and use language that clearly communicates that substance use disorder is a chronic medical condition, that emphasizes treatment (especially medication and behavioral health), and that promotes recovery (see Table 1) (31, 33, 34). Finally, it is important to note that “stigma catches up” and therefore language that reflects the dignity and humanity of pregnant and parenting people who use drugs is constantly changing. As healthcare professionals, it will be necessary to adapt our terminology as needed.
Table 1. Addressing stigma by changing the language we use.
Screening and assessment
Substance use and use disorder are common—nearly 1 in 5 pregnant women report any substance (including tobacco, alcohol, or illicit substances) within the past month, and rates of opioids, cannabis, and stimulants in pregnancy have increased in the past decade (2).
Universal verbal screening for substance use and misuse using a validated instrument is recommended as a routine part of prenatal care by professional societies and public health agencies (8–11, 35, 36). In addition, participation in screening is considered voluntary and rests upon the bioethical principle of autonomy and opposition to coercion (see Table 2) (36–38). Hence, it is recommended that providers ask permission prior to screening and recognize the patient's right of refusal if screening is declined. However, universal screening is vastly underutilized and “risk based” screening persists—a practice that operationalizes and perpetuates stigma and with no improvement of diagnostic accuracy (15, 39).
Table 2. Tips for addressing mistrust and making clinical care welcoming.
There are multiple validated tools to identify problematic substance use including maternal interview and screening questionnaires. Although many screening instruments have been used in pregnancy, only two studies have directly compared the screening instrument performance in pregnancy. Ondersma et al compared 5 instruments: the Substance Use Risk Profile—Pregnancy (SURP-P), CRAFFT (acronym for five-item screener with items related to car, relax, alone, forget, friends and trouble), 5Ps (parents, peers, partner, pregnancy, past), Wayne Indirect Drug Use Screener (WIDUS), and the National Institute on Drug Abuse (NIDA) Quick Screen (40). Coleman-Cowger et al compared 3 instruments: 4P's Plus, NIDA Quick Screen-ASSIST, and the SURP-P (41). No instrument was superior in any of the analyses. Therefore, it is recommended that providers use whatever validated tool is most able to be integrated into the electronic health record.
Drug screening captures behaviors related to substance use. In contrast, drug testing is the evaluation of a biological matrix (such as urine, hair, or meconium) for the presence of drug metabolites or parent compounds. Drug testing is not recommended as an appropriate means to identify substance use or misuse, much less addiction (8, 36). The information obtained from a drug test is not uniform as the time of detection varies greatly across substances. In addition, both false positive and false negative results are common in drug tests (42, 43). Furthermore, the American Society of Addiction Medicine (ASAM) recommendations are clear that definitive testing (i.e., gas chromatography) is required “when the results will inform a decision with major clinical or non-clinical implications for the patient” which, given the realities of child welfare reporting, would be any drug test in pregnancy especially during the birthing hospitalization (44).
Screening is not diagnosis, and a positive screen must be followed up with the assessment of DSM criteria for the establishment of diagnosis. Screening helps to stratify patients into risk categories: those that meet criteria for a use disorder need treatment; those with “moderate risk” (history of use but without addiction) should receive a brief intervention grounded in motivational interviewing and (more) frequent follow up visits; and those with low risk (no past or current use) should receive brief advice and acknowledgement of their healthy behaviors (11).
Although screening is recommended, patients may be legitimately fearful of disclosure, including the threat of legal repercussions (45). It is important that all providers continue to create a safe and non-judgmental environment that encourages engagement in care. Providers should be honest and transparent regarding how information obtained from either screening or testing is shared with external agencies, including child welfare, and overreporting (use or positive drug testing without protective concerns) should be discouraged.
Treatment
SUD is a chronic medical condition and like other chronic conditions, outcomes are greatly improved by treatment (46). There is, however, a large gap in access to treatment (both medication and behavioral) by substance type, with the highest rate of treatment for opioids and the lowest for alcohol (17). The marked gap in treatment is further magnified by racial inequities. Compared to White individuals, Black and Hispanic populations are less likely to receive any SUD treatment, less likely to receive medication for OUD (MOUD), and if in treatment, receive lower doses of MOUD (18, 47).
Among people with SUD, polysubstance use is common and co-occurring substance use and use disorders can be treated simultaneously. Ideally, care should be delivered in a comprehensive and co-located capacity, that is, through the integration of addiction treatment and prenatal care. Integrated care models have been described since the 1970s, are considered the “standard of care”, and are associated with improved birth outcomes (7, 20). However, some individuals need a higher level of care. ASAM categorizes addiction treatment along levels of care that range from outpatient to residential and inpatient (48). Level of care should be evaluated at treatment intake and throughout, especially if treatment is failing a patient at a particular moment. Medication should be available throughout levels of care as should childcare services, although both medication and childcare are often absent and are hence barriers to care for pregnant and parenting people (49, 50). In addition, treatment should address concomitant mental health disorders (51). Below we discuss treatment and outcomes by substance type.
Opioids
From 1999 to 2014, the rate of OUD complicating birth has increased by more than 4-fold and in some states the rate has increased nearly 10-fold, yet OUD treatment is still stigmatized and underutilized (8, 52). Despite public health and professional society recommendations supporting MOUD (14), pregnant and postpartum individuals with OUD continue to face barriers to treatment, including stigma (53), discrimination, lack of knowledgeable clinicians (54), and misinformation about NAS (55). Available data regarding negative fetal effects of opioids are inconsistent and some of the literature is cross-sectional, retrospective (hence subject to recall and other bias), or outcome assessments are not masked. However, there is no evidence that MOUD (either buprenorphine or methadone) increases risk of congenital anomalies (56).
MOUD, including methadone (a full mu-agonist and weak NMDA receptor antagonist), buprenorphine (partial mu-agonist with a high affinity for the mu-opioid receptor and partial mu-antagonist) and naltrexone (nonselective opioid receptor antagonist), save lives and are the standard OUD treatment—among pregnant and postpartum individuals (8, 36). MOUD improve both substance use and pregnancy outcomes and decrease overdose risk compared with no treatment (57). Evidence for the safety and efficacy of methadone and buprenorphine is the strongest, however due to recent studies confirming safety and efficacy of the buprenorphine-naloxone combination product and persistent barriers to outpatient methadone access in the current flawed system, buprenorphine use is increasing (58), and a multisite injectable buprenorphine trial in pregnancy is ongoing (59). Detoxification, or medically supervised withdrawal, is not recommended in pregnancy. Naltrexone is the newest approved MOUD and the least studied in pregnancy; the urgency to close this research gap is currently being addressed in an ongoing multisite trial (59). Detoxification is not treatment, is associated with return to use and not associated with a decrease in NAS (60). However, it is important to respect patient autonomy and it may be attempted after shared decision making with counseling on the safety of detoxification and the risk of return to use (61).
Although MOUD with either methadone or buprenorphine are the safest and most effective treatment for OUD in pregnancy, most people with OUD receive no treatment in pregnancy (17), only 50% of people admitted to specialty addiction treatment programs receive medication (62), and there are marked racial inequities in medication receipt, type, and dose. Black pregnant people are less likely to receive medication compared to White pregnant people and overall, more likely to receive methadone than buprenorphine (18). Even among those who receive methadone, mean daily doses are highest for White (144.9 mg) compared to Black (97.5 mg) pregnant people (47).
MOUD dose (methadone or buprenorphine) is not correlated with neonatal abstinence syndrome (63, 64), however there is decreased incidence and severity of NAS associated with buprenorphine compared to methadone (65). Behavioral interventions, such as contingency management, cognitive behavioral therapy, and family therapy, are helpful (66, 67) but absence of or non-adherence with behavioral health should not be used as justification to withhold MOUD (68). Optimal duration of treatment with MOUD is not established and for some individuals may be lifelong, however MOUD discontinuation postpartum is common and is associated with increased rates of return to use, overdose, and death (57, 69). Providers should be aware of community resources including peer recovery support services and “12 step programs” because use of peer services is associated with increased attendance at OUD medical appointments (70). Recent qualitative studies suggest that peer services are valued among pregnant and postpartum individuals with OUD and are increasingly accessible through telehealth and online (71).
Naloxone (short-acting opioid antagonist) rapidly reverses opioid overdose and is not considered MOUD. Given the increase in intentional and unintentional fentanyl use, pregnant and postpartum individuals and their supports should be counseled on the increased risk of overdose, need for immediate naloxone administration in case of overdose, and to call emergency medical services because multiple doses of naloxone and/or oxygen support may be needed (72). Because fentanyl is increasing throughout the US and there are increasing reports of xylazine (alpha-2 adrenergic agonist) in the drug supply, further training in overdose prevention and management is needed. Xylazine is sympatholytic causing severe sedation, respiratory depression and slowed heart rate, further complicating overdose prevention and management, therefore provider training is needed on co-prescription of naloxone, education on naloxone-resistant overdoses, and increasing need for respiratory support in xylazine-opioid combination use and patient support training on overdose recognition (73).
Alcohol
Binge alcohol use—4 or more drinks on a single occasion for women—is common in pregnant individuals in the past month, yet rates of alcohol use and alcohol use disorder (AUD) are likely gravely miscalculated (2). Although alcohol is an established teratogen and there is no known safe lower limit of alcohol exposure. Fetal alcohol syndrome (FAS) is the leading modifiable cause of intellectual disability and developmental delay in the US, with a similar rate to Down syndrome, and 20 times more common in the US (1.95/1,000) than in Europe (0.08/1,000) (74). All individuals who report alcohol use should be evaluated for AUD and referred to treatment to avoid withdrawal which can be life-threatening. Untreated withdrawal is associated with a nearly 5% subsequent yearly mortality rate (75). The American Society of Addiction Medicine recommends initial inpatient management for individuals at risk of severe withdrawal, which includes pregnancy (76). Withdrawal management alone is not addiction treatment—the mainstay of treatment for AUD is medication with behavioral interventions because behavioral interventions alone are associated with high rates of return to use (77, 78). There are three approved medications for AUD: disulfiram (aldehyde dehydrogenase inhibitor), acamprosate (glutamate/GABA neuromodulator) and naltrexone (mu-opioid receptor antagonist). Due to the exclusion of pregnant individuals from medication trials, there is no evidence base regarding safety and effectiveness in pregnancy (79), and these medications are vastly underutilized. However, medications for AUD are almost certainly less harmful than untreated AUD and should be considered in the clinical care for pregnant and postpartum individuals (80, 81).
Nicotine/tobacco
There is significantly higher tobacco use in individuals who have other SUDs compared to those with no SUD and this does not change dramatically among pregnant and parenting individuals. Although 50% of individuals stop smoking during pregnancy, up to 90% resume within 1 year postpartum (82). Behavioral interventions, such as cognitive behavioral therapy (CBT) or contingency management, remain the standard treatment for smoking cessation (83). Nicotine replacement therapy (NRT) has not been shown to be beneficial in smoking cessation in pregnancy, however, NRT can reduce maternal and fetal exposure to nicotine, mitigate maternal lung disease, and reduce second and third-hand smoke exposure postpartum. Although there are limited data on bupropion and varenicline use in pregnancy, a recent analysis suggests safety of bupropion both in pregnancy and breast/chestfeeding (84). Medications decisions, including NRT, should be individual clinical decisions, balancing risks and benefits, and center on patient autonomy.
Cocaine
Cocaine use in pregnancy has a shameful history of unscientific and racist rhetoric, filled with false claims of adverse child neurodevelopmental outcomes, teratogenicity, and lifelong mental and physical disability (53, 85–87). It is important to acknowledge that despite the research disproving these claims, significant stigma persists particularly for Black individuals. Because cocaine can cause hypertensive emergencies and increase myocardial oxygen demand, in utero exposure can be associated with preterm birth, placental abruption, preeclampsia-like symptoms, maternal coronary artery vasospasm, and myocardial ischemia, infarction or arrhythmia (88). A symptom of both the ongoing “war on drugs” and the subsequent unequal burden of “crack” or crystal cocaine use in Black and poor communities, research on cocaine use disorder (CUD) treatment is limited and there are no medications approved for (CUD) (89). There is modest evidence for bupropion, topiramate, and psychostimulants, but none of these have been studied in pregnancy (89). There is increasing evidence that contingency management increases abstinence, and behavioral modalities remain the mainstay of treatment in pregnancy (67, 90).
Methamphetamines
Methamphetamine is the second most used illicit substance globally and use has been increasing in pregnancy particularly in Western and rural regions of the US (present in 1% of births) and now also in Eastern and urban regions (particularly via injection and not inhalation) (91). Concurrent opioid and methamphetamine use and methamphetamine-related overdose rates are rapidly increasing globally and this trend is being described as “a new or fourth wave in the opioid crisis” (92). Methamphetamine has vasoconstrictive properties and is associated with preterm birth, low birth weight, and small for gestational age (93), but it not associated with placental abruption. The IDEAL (Infant Development and Lifestyle) is a prospective multisite cohort study designed to prevent repeating the racism and misleading science of early cocaine research (94) Results from IDEAL have demonstrated no differences in child development or motor skills at 3 years of age (95). There are no medications approved for treatment of methamphetamine use disorder (MUD) and none have been studied in pregnancy, however a systematic review of different medications and combinations, demonstrated possible positive effects on treatment outcomes most consistently with stimulant agonists, naltrexone and topiramate (96). There is also some evidence that mirtazapine results in a small reduction in methamphetamine use, less methamphetamine-positive urine tests, and decreased high risk sexual behaviors, yet it does not increase retention in treatment (97). Treatment rests primarily contingency management and motivational interviewing (67, 90).
Benzodiazepines
Benzodiazepines have benefit in the management of acute seizures and alcohol withdrawal, but they do not improve outcomes in the chronic management of depression or anxiety beyond the first month of treatment (98). Despite this, there are no national guidelines for prescribing and few interventions have been evaluated to reduce benzodiazepine-related problems (99). Yet benzodiazepines are ubiquitous and play a large role in the overdose crisis in the United States because concurrent use with opioids increases the risk of opioid-related accidental poisoning, particularly in the first 90 days of a new prescription (100). Benzodiazepines are prescribed more commonly to women as compared to men and may be over prescribed in pregnant and parenting individuals (101). Benzodiazepines are one of the most frequently prescribed medications in pregnancy: in privately insured individuals, 0.8% have a benzodiazepine prescription (102). Although concurrent use of benzodiazepines and opioids (including MOUD) is associated with overdose and death, MOUD should be continued despite patient report or detection of benzodiazepine use (103). Although in utero exposure does not suggest teratogenicity or negative effects on neurocognitive development in children, extended in utero exposure can cause neonatal withdrawal symptoms similar to opioids and is associated with longer NAS treatment especially in the context of methadone (104–106).
Similar to alcohol, abrupt cessation of benzodiazepines can be severe and life-threatening. Acute withdrawal is assessed and managed similarly to alcohol withdrawal; however benzodiazepine use disorder (BUD) requires more than withdrawal management and often includes gradual outpatient tapers, which have been shown to have higher efficacy as compared to short-term inpatient care (107). Effective treatment for BUD includes cognitive behavioral therapy and given the similarities with AUD should include consideration of medications for AUD (90).
Cannabis
Cannabis is the most common substance used in the United States that is illegal under federal law. Approximately 5% of pregnant individuals report past-month cannabis use (2). Many individuals use cannabis to self-treat medical and mental health conditions prior to pregnancy and can continue this use into and during pregnancy especially for pregnancy specific symptoms such as nausea and vomiting (108, 109). Providers should also be aware of the increasing number of synthetic cannabinoids—also known as spice or K2—and of the limited data on maternal and perinatal outcomes (110). Synthetic cannabinoids have more potent effects than natural cannabinoids including respiratory distress, hypertension, acute renal failure, coagulopathy, psychosis, suicidal ideation, and death (111). The American College of Obstetricians and Gynecology, the American Academy of Pediatrics, and the US Surgeon General all advise against medical or recreational cannabis during preconception and pregnancy and lactation due to unknown and potential harmful maternal, fetal and child outcomes (112). Although there are no approved medications for cannabis use disorder, there is some evidence for consideration of N-acetylcysteine and gabapentin and there is good evidence for behavioral interventions including motivational enhancements, cognitive behavioral therapy, and contingency management (113).
The birthing hospitalization
Prior experiences of discrimination in healthcare settings, concern about pain management, and legitimate fear regarding child welfare intervention make the birthing hospitalization a stressful time for pregnant people with SUD.
For patients receiving MOUD, the medication should be continued throughout the birthing hospitalization (8, 36, 90). Dose verification through medical record review, prescription drug monitoring program, or contact with the opioid treatment program is helpful. MOUD does not provide analgesia, should be considered the patient's “baseline”, and people with OUD may require more analgesia compared to people without OUD. Providers discuss options for pain control during prenatal care and upon admission to the birthing hospitalization using a trauma-informed approach founded upon shared decision-making. Some patients may have fears about how opioids analgesia could impact their recovery or may want to avoid opioids altogether, so ascertaining patient preference for pain management is paramount.
All MOUD (including methadone, buprenorphine, and naltrexone) should be continued including perioperatively for scheduled cesarean delivery to decrease the risk for both return to use and a difficult transition back to MOUD after acute pain has resolved (114). Existing research confirms better pain control with protocols that account for increased pain sensitivity and higher opioid tolerance in patients with OUD (115). This approach requires higher doses of short-acting opioids and a multimodal analgesic regimen.
Labor analgesia should be multi-modal and include topical, regional, and systemic approaches. Short-acting opioids can be safely prescribed and co-used with MOUD, including those on injectable naltrexone. Again, discussion of patient preference and a safety plan for opioids at home is crucial. Some patients may want opioids while in the hospital but may not want to have a prescription on discharge, while others may feel safer with a lock box, additional support, or family involvement. All people who may witness an overdose, including people with OUD and those receiving MOUD, should be co-prescribed naloxone upon hospital discharge (116, 117).
The American Academy of Pediatrics state that maternal substance use is “not a categorical contraindication to breastfeeding” (118). Breast or chest feeding is an important nonpharmacologic management of NAS and can be beneficial for all patients in recovery, although sociodemographic characteristics, race, and mental health status are all associated with decreased provider and nursing support of breastfeeding (119). Due to insufficient data on neurodevelopmental outcomes or risk of vertical infection transmission, breastfeeding in the context of continued illicit substance use is not encouraged. Clinical decisions regarding breastfeeding during the birthing hospitalization, however, must rest on the principles of bioethics including respect for bodily autonomy and adequate support to those who choose to breastfeed should be provided (118).
Assessment of behavioral health is an important component of admission and management during the birthing hospitalization. For people who present with untreated substance use disorder, the birthing hospitalization is a critical time to initiate treatment and bridge to continuing care. However, drug testing is grossly overused and misinterpreted despite professional society recommendations against routine drug testing of either the pregnant person or the newborn (120). A positive drug test result is not evidence of health or ill health, is not listed as a criterion for newborn discharge and is not essential to the diagnosis of NAS (121, 122). Yet presumptive positive drug test results are often reflexively reported to child welfare. This practice of “test and report” which reveals the drug test as not clinical but a primarily moral or parenting test, has been criticized by ACOG: “The laws, regulations, and policies that require health care practitioners and human service workers to respond to substance use and substance use disorder in a primarily punitive way, require health care providers to function as agents of law enforcement” (123). Although rare States mandate drug testing during the birthing hospitalization, Federal legislation is clear. CAPTA (the Child Abuse Prevention and Treatment Act) neither requires testing, nor the reporting of positive test results to child welfare and states unequivocally that substance use is not in-and-of-itself an indication of child abuse. Providers rarely understand the consequences of a report (124) and operate under the false assumption that an agency of surveillance can provide necessary services to families (125). Rates of child removal attributed to substance use have doubled in recent years, and the majority of infant reports come from health professionals (126).
As previously discussed, for all patients, it is crucial to prescribe naloxone upon discharge, particularly if co-prescribing opioids, but the need for naloxone should be assessed in all patients with OUD. Additionally, many geographic regions increasingly have a contaminated/poisoned illicit drug supply and therefore, there is an increase in unintentional fentanyl exposure. Safety around the potential for unintentional fentanyl use (i.e., in those with non-opioid SUD) should be addressed and patients with any SUD should be encouraged to have a prescription for or access to naloxone.
Postpartum
Postpartum is a time of increased vulnerabilities for return to use, SUD recurrence, overdose, and overdose death. Care, which had been focused on the pregnant person, becomes less frequent and shifts from mother to infant and from medical to non-medical domains. Insurance churn, including loss of Medicaid coverage, contributes to care discontinuation especially for addiction treatment (57, 69, 127).
Maternal deaths have been increasing in the US and recent population-based data shows that the peak incidence of self-harm related death (specifically overdose and suicide) is 9–12 months postpartum (128–131). In contrast to a global trend in reduction of pregnant- and postpartum-related deaths, a large observational study reported a 26% increase in maternal deaths in 48 US states from 2000 to 2014 (131). Rates of discontinuation of MOUD have been shown to be greater than 50% at 6 months postpartum. Drug deaths are now the leading cause of maternal death in the US (69, 129). Naloxone prescribing and training is essential at delivery hospitalization discharge as is linkage to continuing care.
High rates of co-occurring mental health and substance use disorders put postpartum persons with SUD at especially high risk of psychiatric morbidity and mortality. Having any substance use disorder or use of illicit substances is associated with at least a threefold greater suicide risk (132). Additionally, many pregnant persons stop treatment, particularly medications, during pregnancy and do not resume immediately postpartum (133). Therefore, postpartum persons with SUD should be screened early and repeatedly for anxiety, depression and IPV in the postpartum period and should continue to follow closely with their addiction, obstetric and behavior health providers. Updated in 2018, ACOG recommends screening for depression, anxiety and IPV in all trimesters and the postpartum period and now recommends more and earlier postpartum follow up visits (134).
Appropriate continuing care should include postpartum services, Hepatitis C virus (HCV) treatment (if applicable), assessment of risk and discussion of initiation of pre-exposure prophylaxis (PrEP) for HIV, family planning counseling, behavioral health, peer recovery support and a “warm handoff” transition to primary care. Providers can partner with community-based organizations, peer support services, home visiting, and Early Head Start to support families and keep people engaged in care. The standard single postpartum visit from the prenatal care provider is likely insufficient for the needs of parenting people with SUD. ACOG recommends redesigning postpartum care to optimize health by focusing on care as an ongoing process with services and support tailored to individual and family needs (135). Postpartum care includes reproductive life planning and the provision of contraception within a shared decision-making context. Having an SUD is associated with higher rates of unintended pregnancy compared to the general population, especially in the immediate postpartum period (136)—86% of persons with SUD did not plan their pregnancy compared to 31%–47% in the general population (137). Contraceptive use, particularly the more effective LARC methods, among persons with SUD is lower (138, 139), however current data suggests that lower uptake of reproductive health services in this population is complex. A recent study found an association between increased postpartum contraceptive use and increased prenatal care visits, OBGYN buprenorphine prescribing and increased postpartum visits (140). Furthermore, HCV infection is rapidly increasing among reproductive-aged persons with injection drug use (141) leading to an ACOG recommendation for universal HCV screening in pregnancy (142). Enhanced engagement in care during pregnancy should not be a missed opportunity to provide persons with OUD access to treatment of other medical disorders such as HCV treatment.
Conclusion
Although drug use decreases significantly during pregnancy and continues to decrease from the first to the third trimester, overall substance use—including opioids, alcohol, cannabis, and cocaine—is increasing among pregnant people in the US. Substance use trends, treatment access, and child welfare policies differ widely by state and therefore it is important that all providers understand their specific geographic resources and climate. SUD outcomes are significantly improved by treatment, however a large gap in treatment access persists. Among those with need for SUD treatment, only 11% report receiving treatment. Although pregnant people are considered a priority population, structural and racial barriers that exist for all people with SUD persist through pregnancy and worsen postpartum in both access to and adequacy of treatment. Providers for the dyad can serve as another point in the healthcare system at which patients can be appropriately screened and adequately referred to treatment, and therefore should be aware of all resources available to aid in breaking the cycle (see Table 3). Although it is established that punitive substance use policies increase adverse perinatal outcomes (143, 144), the unjust and inhuman separation of the dyad is not widely acknowledged (145, 146). In short, care should be both evidence-based and person-centered, reflect science and public health but also grounded in human rights, human dignity, and recognize the unique burdens we place on pregnant people, their bodies, and their minds.
Table 3. Resources for providers.
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Terplan M. Substance use and use disorder in pregnancy and postpartum. Int Rev Psychiatry. (2021) 33(6):501. doi: 10.1080/09540261.2021.1981098
2. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health, ed. N.S.H.-. HHS Publication No. PEP21-07-01-003. 2021, Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
3. Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996–1998. Obstet Gynecol. (2003) 101(2):374–9. doi: 10.1016/s0029-7844(02)02588-7
4. Peltier MR, Roberts W, Verplaetse TL, Burke C, Zakiniaeiz Y, Moore K, et al. Licit and illicit drug use across trimesters in pregnant women endorsing past-year substance use: results from national survey on drug use and health (2009–2019). Arch Womens Ment Health. (2022) 25(4):819–27. doi: 10.1007/s00737-022-01244-6
5. Martin CE, Terplan M, Krans EE. Pain, opioids, and pregnancy: historical context and medical management. Clin Perinatol. (2019) 46(4):833–47. doi: 10.1016/j.clp.2019.08.013
6. Medicine, A.S.o.A. Definition of addiction. 2019. Available at: https://www.asam.org/quality-care/definition-of-addiction (Accessed September 15, 2022).
7. Kotelchuck M, Cheng ER, Belanoff C, Cabral HJ, Babakhanlou-Chase H, Derrington TM, et al. The prevalence and impact of substance use disorder and treatment on maternal obstetric experiences and birth outcomes among singleton deliveries in Massachusetts. Matern Child Health J. (2017) 21(4):893–902. doi: 10.1007/s10995-016-2190-y
8. Committee opinion No. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. (2017) 130(2):e81–94. doi: 10.1097/AOG.0000000000002235
9. Patrick SW, Schiff DM. A public health response to opioid use in pregnancy. Pediatrics. (2017) 139(3):e20164070. doi: 10.1542/peds.2016-4070
10. Ecker J, Abuhamad A, Hill W, Bailit J, Bateman BT, Berghella V, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the society for maternal-fetal medicine, American college of obstetricians and gynecologists, and American society of addiction medicine. Am J Obstet Gynecol. (2019) 221(1):B5–B28. doi: 10.1016/j.ajog.2019.03.022
11. Wright TE, Terplan M, Ondersma SJ, Yonkers K, Chang G, Creanga AA, et al. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. (2016) 215(5):539–47. doi: 10.1016/j.ajog.2016.06.038
12. Wong S, Ordean A, Kahan M. Substance use in pregnancy. J Obstet Gynaecol Can. (2011) 33(4):367–84. doi: 10.1016/S1701-2163(16)34855-1
13. Klaman SL, Isaacs K, Leopold A, Perpich J, Hayashi S, Vender J. Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. J Addict Med. (2017) 11(3):178–90. doi: 10.1097/ADM.0000000000000308
14. Reddy UM, Davis JM, Ren Z, Greene MF; Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop Invited Speakers. Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the eunice kennedy shriver national institute of child health and human development, American college of obstetricians and gynecologists, American academy of pediatrics, society for maternal-fetal medicine, centers for disease control and prevention, and the march of dimes foundation. Obstet Gynecol. (2017) 130(1):10–28. doi: 10.1097/AOG.0000000000002054
15. Ko JY, Tong VT, Haight SC, Terplan M, Stark L, Snead C, et al. Obstetrician–gynecologists’ practices and attitudes on substance use screening during pregnancy. J Perinatol. (2020) 40(3):422–32. doi: 10.1038/s41372-019-0542-3
16. Koy JY, Nielsen T, Hoeppner BB, Terplan W, Hansen H, Bernson D, et al. Obstetrician–gynecologists’ practice patterns related to opioid use during pregnancy and postpartum—United States, 2017. J Perinatol. (2020) 40(3):412–21. doi: 10.1038/s41372-019-0535-2
17. Martin CE, Scialli A, Terplan M. Unmet substance use disorder treatment need among reproductive age women. Drug Alcohol Depend. (2020) 206:107679. doi: 10.1016/j.drugalcdep.2019.107679
18. Schiff DM, Nielsen T, Hoeppner BB, Terplan W, Hansen H, Bernson D, et al. Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts. JAMA Network Open. (2020) 3(5):e205734. doi: 10.1001/jamanetworkopen.2020.5734
19. Connaughton JF Jr, Finnegan LP, Schut J, Emich JP. Current concepts in the management of the pregnant opiate addict. Addict Dis. (1975) 2(1-2):21–35. PMID: 1163364
20. Finnegan LP. Management of pregnant drug-dependent women. Ann N Y Acad Sci. (1978) 311:135–46. doi: 10.1111/j.1749-6632.1978.tb16770.x
21. Terplan M. Women and the opioid crisis: historical context and public health solutions. Fertil Steril. (2017) 108(2):195–9. doi: 10.1016/j.fertnstert.2017.06.007
22. Wakeman SE, Bryant A, Harrison N. Redefining child protection: addressing the Harms of structural racism and punitive approaches for birthing people, dyads, and families affected by substance use. Obstet Gynecol. (2022) 140(2):167–73. doi: 10.1097/AOG.0000000000004786
23. Nguemeni Tiako MJ, Sweeney L. The government's involvement in prenatal drug testing may be toxic. Matern Child Health J. (2022) 26(4):761–3. doi: 10.1007/s10995-020-03110-2
24. Goodwin M. Policing the womb: Invisible women and the criminalization of motherhood. Cambridge University Press (2020).
25. Kors S, Kurdziel-Adams G, Towers C, Fortner K, Macfie J. Sexual abuse as a risk factor for opioid misuse in pregnancy. J Child Sex Abus. (2022) 31(5):538–49. doi: 10.1080/10538712.2022.2056104
26. Torchalla I, Linden IA, Strehlau V, Neilson EK, Krausz M. “Like a lots happened with my whole childhood”: violence, trauma, and addiction in pregnant and postpartum women from Vancouver's downtown eastside. Harm Reduct J. (2015) 11:34. doi: 10.1186/1477-7517-11-34
27. Sanjuan PM, Pearson MR, Fokas K, Leeman LM. A mother's bond: an ecological momentary assessment study of posttraumatic stress disorder symptoms and substance craving during pregnancy. Psychol Addict Behav. (2020) 34(2):269–80. doi: 10.1037/adb0000543
28. Leiner C, Cody T, Mullins N, Ramage M, Ostrach BMM. “The elephant in the room;” a qualitative study of perinatal fears in opioid use disorder treatment in southern appalachia. BMC Pregnancy Childbirth. (2021) 21(1):143. doi: 10.1186/s12884-021-03596-w
29. Paris R, Herriott AL, Maru M, Hackign SE, Sommer AR. Secrecy versus disclosure: women with substance use disorders share experiences in help seeking during pregnancy. Matern Child Health J. (2020) 24(11):1396–403. doi: 10.1007/s10995-020-03006-1
30. Berman H, Mason R, Hall J, Rodger S, Classen CC, Evans MK, Ross LE, et al. Laboring to mother in the context of past trauma: the transition to motherhood. Qual Health Res. (2014) 24(9):1253–64. doi: 10.1177/1049732314521902
31. Schiff DM, Halvorson AE, Dupont W, Davis MM, Patrick SW. Impact of stigmatizing language describing opioid-exposed mother infant dyads: a randomized case vignette study. Subst Abus. (2022) 43(1):551–5. doi: 10.1080/08897077.2021.1975866
32. Schiff DM, Stoltman JJK, Nielsen T, Myers S, Nolan M, Terplan M, et al. Assessing stigma towards substance use in pregnancy: a randomized study testing the impact of stigmatizing language and type of opioid use on attitudes toward mothers with opioid use disorder. J Addict Med. (2022) 16(1):77–83. doi: 10.1097/ADM.0000000000000832
33. Atayde AMP, Hauc SC, Bessette LG, Danckers H, Saitz R. Changing the narrative: A call to end stigmatizing terminology related to substance use disorders. Addict Res Theory. 29(5):1–4. doi: 10.1080/16066359.2021.1875215
34. Saitz R. International statement recommending against the use of terminology that can stigmatize people. J Addict Med. (2016) 10(1):1–2. doi: 10.1097/ADM.0000000000000178
35. Medicine, A.S.o.A. Substance use and substance use disorder among pregnant and postpartum people (2022). Available at: https://www.asam.org/advocacy/public-policy-statements/details/public-policy-statements/2022/10/12/substance-use-and-substance-use-disorder-among-pregnant-and-postpartum-people (Accessed January 11, 2023).
36. Administration, S.A.a.M.H.S. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants, ed. H.P.N.S. 18-5054. Rockville, MD: Substance Abuse and Mental Health Services Administration (2018).
37. Committee opinion 664: refusal of medically recommended treatment during pregnancy. Obstet Gynecol, 2016. 127:e175–82. doi: 10.1097/AOG.0000000000001485
38. Association, A.M. Legal interventions during pregnancy. Policy statement H-420.969 (2018). Available at: https://policysearch.ama-assn.org/policyfinder/detail/women?uri=%2FAMADoc%2FHOD.xml-0-3712.xml (Accessed September 15, 2022).
39. Kerker BD, Horwitz SM, Leventhal JM. Patients’ characteristics and providers’ attitudes: predictors of screening pregnant women for illicit substance use. Child Abuse Negl. (2004) 28(2):209–23. doi: 10.1016/j.chiabu.2003.07.004
40. Ondersma SJ, Chang G, Blake-Lamb T, Gilstad-Hayden K, Orav J, Beatty JR, et al. Accuracy of five self-report screening instruments for substance use in pregnancy. Addiction. (2019) 114(9):1683–93. doi: 10.1111/add.14651
41. Coleman-Cowger V, Oga EA, Peters EN, Trocin KE, Koszowski B, Mark K. Accuracy of three screening tools for prenatal substance use. Obstet Gynecol. (2019) 133(5):952–61. doi: 10.1097/AOG.0000000000003230
42. Wanar A, Isley BC, Saia K, Field TA. False-positive fentanyl urine detection after initiation of labetalol treatment for hypertension in pregnancy: a case report. J Addict Med. (2012) 16(6):e417–9. doi: 10.1097/ADM.0000000000001010
43. Yee LM, Wu D. False-positive amphetamine toxicology screen results in three pregnant women using labetalol. Obstet Gynecol. (2011) 117(Part 2):503–6. doi: 10.1097/AOG.0b013e318206c07c
44. Jarvis M, Williams J, Hurford M, Lindsay D, Lincoln P, Giles L, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. (2017) 11(3):163–73. doi: 10.1097/ADM.0000000000000323
45. Stone R. Pregnant women and substance use: fear, stigma, and barriers to care. Health Justice. (2015) 3(1):1–15. doi: 10.1186/s40352-015-0015-5
46. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. J Am Med Assoc. (2000) 284(13):1689–95. doi: 10.1001/jama.284.13.1689
47. Rosenthal EW, Short VL, Cruz Y, Barber C, Baxter JK, Abatemarco DJ, et al. Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder. J Subst Abuse Treat. (2021) 131:108454. doi: 10.1016/j.jsat.2021.108454
48. Gastfriend DR, Mee-Lee D. Thirty years of TheASAMCriteria: a report card. Psychiatr Clin North Am. (2022) 45(3):593–609. doi: 10.1016/j.psc.2022.05.008
49. Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. (2020) 2020. doi: 10.31478/202004b
50. Terplan M, Longinaker N, Appel L. Women-centered drug treatment services and need in the United States, 2002-2009. Am J Public Health. (2015) 105(11):e50–4. doi: 10.2105/AJPH.2015.302821
51. Clark HW. Residential substance abuse treatment for pregnant and postpartum women and their children: treatment and policy implications. Child Welfare. (2001) 80(2):179–98. PMID: 11291900
52. Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization - United States, 1999-2014. Morb Mortal Wkly Rep. (2018) 67(31):845–9. doi: 10.15585/mmwr.mm6731a1
53. Terplan M, Kennedy-Hendricks A, Chisolm MS. Prenatal substance use: exploring assumptions of maternal unfitness. Subst Abuse. (2015) 9(Suppl 2):1–4. doi: 10.4137/SART.S23328
54. Clearly EM, Smid MC, Charles JE, Costantine MM, Saade G, Rood KM, et al. Buprenorphine X-waiver exemption - beyond the basics for the obstetrical provider. Am J Obstet Gynecol MFM. (2021) 3(6):100451. doi: 10.1016/j.ajogmf.2021.100451
55. Loyal J, Nguyen VN, Picagli D, Petrucelli A, O'Mara E, Grossman MR, et al. Postpartum nurses’ experience caring for infants with neonatal abstinence syndrome. Hosp Pediatr. (2019) 9(8):601–7. doi: 10.1542/hpeds.2019-0087
56. Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle L, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. (2016) 111(12):2115–28. doi: 10.1111/add.13462
57. Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol. (2018) 132(2):466–74. doi: 10.1097/AOG.0000000000002734
58. Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. (2019) 200:34–9. doi: 10.1016/j.drugalcdep.2019.02.031
59. Winhusen T, Lofwall M, Jones HE, Wilder C, Lindblad R, Schiff DM, et al. Medication treatment for opioid use disorder in expectant mothers (MOMs): design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemp Clin Trials. (2020) 93:106014. doi: 10.1016/j.cct.2020.106014
60. Terplan M, Laird H, Hand D, Wright TE, Premkumar A, Martin CE, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. (2018) 131(5):803–14. doi: 10.1097/AOG.0000000000002562
61. Jones HE, Terplan M, Meyer M. Medically assisted withdrawal (detoxification): considering the mother-infant dyad. J Addict Med. (2017) 11(2):90–2. doi: 10.1097/ADM.0000000000000289
62. Short VL, Hand DJ, MacAfee L, Abatemarco DJ, Terplan M. Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States. J Subst Abuse Treat. (2018) 89:67–74. doi: 10.1016/j.jsat.2018.04.003
63. McCarthy JJ. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study: Re Meyer, et al. J Addict Med. (2016) 10(2):133–4. doi: 10.1097/ADM.0000000000000183
64. Wong K, Saver B, Scanlan JM, Gianutsos LP, Bhakta Y, Walsh J, et al. Does maternal buprenorphine dose affect severity or incidence of neonatal abstinence syndrome? J Addict Med. (2018) 12(6):435–41. doi: 10.1097/ADM.0000000000000427
65. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. (2010) 363(24):2320–31. doi: 10.1056/NEJMoa1005359
66. Dugosh K, Abraham A, Seymour B, McLoyd K, Keli JD, Chalk M, et al. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. (2016) 10(2):93–103. doi: 10.1097/ADM.0000000000000193
67. Terplan M, Ramanadhan S, Locke A, Longinaker N, Lui S. Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions. Cochrane Database Syst Rev. (2015) 4:Cd006037. doi: 10.1002/14651858.CD006037.pub3
68. National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives. National Academies Press (2019).
69. Wilder C, Lewis D, Winhusen T. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug Alcohol Depend. (2015) 149:225–31. doi: 10.1016/j.drugalcdep.2015.02.012
70. Kleinman MB, Felton JW, Johnson A, Magidson JF. “I have to be around people that are doing what i'm doing”: the importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities. J Subst Abuse Treat. (2021) 122:108182. doi: 10.1016/j.jsat.2020.108182
71. Fallin-Bennett A, Elswick A, Ashford K. Peer support specialists and perinatal opioid use disorder: someone that's been there, lived it, seen it. Addict Behav. (2020) 102:106204. doi: 10.1016/j.addbeh.2019.106204
72. Blandthorn J, Bowman E, Leung L, Bonomo Y, Dietze P. Managing opioid overdose in pregnancy with take-home naloxone. Aust N Z J Obstet Gynaecol. (2018) 58(4):460–2. doi: 10.1111/ajo.12761
73. Haffajee RL, Cherney S, Smart R. Legal requirements and recommendations to prescribe naloxone. Drug Alcohol Depend. (2020) 209:107896. doi: 10.1016/j.drugalcdep.2020.107896
74. May PA, Baete A, Russo J, Elliott AJ, Blankenship J, Kalberg WO, et al. Prevalence and characteristics of fetal alcohol spectrum disorders. Pediatrics. (2014) 134(5):855–66. doi: 10.1542/peds.2013-3319
75. Campos J, Roca L, Gude F, Gonzalez-Quintela A. Long-term mortality of patients admitted to the hospital with alcohol withdrawal syndrome. Alcohol Clin Exp Res. (2011) 35(6):1180–6. doi: 10.1111/j.1530-0277.2011.01451.x
76. Crotty K, Freedman KI, Kampman KM. Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder. J Addict Med. (2020) 14(2):99–112. doi: 10.1097/ADM.0000000000000635
77. Pettinati HM. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. (2005) 15:170–8; discussion 168–9. doi: 10.15288/jsas.2005.s15.170
78. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. J Am Med Assoc. (2006) 295(17):2003–17. doi: 10.1001/jama.295.17.2003
79. Smith EJ, Lui S, Terplan M. Pharmacologic interventions for pregnant women enrolled in alcohol treatment. Cochrane Database Syst Rev. (2009) 2009(3):Cd007361. doi: 10.1002/14651858.CD007361.pub2
80. Kelty E, Terplan M, Greenland M, Preen D. Pharmacotherapies for the treatment of alcohol use disorders during pregnancy: time to reconsider? Drugs. (2021) 81(7):739–48. doi: 10.1007/s40265-021-01509-x
81. DeVido J, Bogunovic O, Weiss RD. Alcohol use disorders in pregnancy. Harv Rev Psychiatry. (2015) 23(2):112–21. doi: 10.1097/HRP.0000000000000070
82. Tong VT, Dietz PM, Morrow B, D'Angelo DV, Farr SL, Rockhill KM. Trends in smoking before, during, and after pregnancy–pregnancy risk assessment monitoring system, United States, 40 sites, 2000-2010. MMWR Surveill Summ. (2013) 62(6):1–19. PMID: 24196750
83. Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, Coleman T. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. (2020) 3(3):Cd010078. doi: 10.1002/14651858.CD010078.pub3
84. McKee SE, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex differences in varenicline efficacy for smoking cessation: a meta-analysis. Nicotine Tob Res. (2016) 18(5):1002–11. doi: 10.1093/ntr/ntv207
85. Coles CD. Saying “goodbye” to the “crack baby”. Neurotoxicol Teratol. (1993) 15(5):290–2; discussion 311–2. doi: 10.1016/0892-0362(93)90024-I
86. Metzl JM, Roberts DE. Structural competency meets structural racism: race, politics, and the structure of medical knowledge. AMA J Ethics. (2014) 16(9):674–90. doi: 10.1001/virtualmentor.2014.16.9.spec1-1409
87. Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. J Am Med Assoc. (2001) 285(12):1613–25. doi: 10.1001/jama.285.12.1613
88. Moore TR, Sorg J, Miller L, Key TC, Resnik R. Hemodynamic effects of intravenous cocaine on the pregnant ewe and fetus. Am J Obstet Gynecol. (1986) 155(4):883–8. doi: 10.1016/S0002-9378(86)80044-8
89. Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for cocaine use disorder-a systematic review and meta-analysis. J Gen Intern Med. (2019) 34(12):2858–73. doi: 10.1007/s11606-019-05074-8
90. Smid MC, Terplan M. What obstetrician-gynecologists should know about substance use disorders in the perinatal period. Obstet Gynecol. (2022) 139(2):317–37. doi: 10.1097/AOG.0000000000004657
91. Lewis D, Kenneally M, Van DenHeuvel C, Byard RW. Methamphetamine deaths: changing trends and diagnostic issues. Med Sci Law. (2021) 61(2):130–7. doi: 10.1177/0025802420986707
92. Jenkins RA, Whitney BM, Nance RM, Allen TM, Cooper HLF, Feinberg J, et al. The rural opioid initiative consortium description: providing evidence to understand the fourth wave of the opioid crisis. Addict Sci Clin Pract. (2022) 17(1):38. doi: 10.1186/s13722-022-00322-5
93. Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. (2006) 118(3):1149–56. doi: 10.1542/peds.2005-2564
94. Kiblawi ZN, Smith LM, Diaz SD, LaGasse LL, Derauf C, Newman E, et al. Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abus. (2014) 35(1):68–73. doi: 10.1080/08897077.2013.814614
95. Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, et al. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol. (2008) 30(1):20–8. doi: 10.1016/j.ntt.2007.09.005
96. Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. (2020) 34(4):337–65. doi: 10.1007/s40263-020-00711-x
97. Naji L, Dennis B, Rosic T, Wiercioch W, Paul J, Worster A, et al. Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: a systematic review and meta-analysis. Drug Alcohol Depend. (2022) 232:109295. doi: 10.1016/j.drugalcdep.2022.109295
98. Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, Furukawa TA. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. (2019) 6(6):Cd001026. doi: 10.1002/14651858.CD001026.pub2
99. Murphy Y, Wilson E, Goldner EM, Fischer B. Benzodiazepine use, misuse, and harm at the population level in Canada: a comprehensive narrative review of data and developments since 1995. Clin Drug Investig. (2016) 36(7):519–30. doi: 10.1007/s40261-016-0397-8
100. Hernandez I, He M, Brooks MM, Zhang Y. Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in medicare part D beneficiaries. JAMA Netw Open. (2018) 1(2):e180919. doi: 10.1001/jamanetworkopen.2018.0919
101. Venkatesh KK, Pate V, Boggess KA, Jones HE, Jonsson Funk M, Smid MC. Trends in opioid and psychotropic prescription in pregnancy in the United States from 2001 to 2015 in a privately insured population: a cross-sectional study. Ann Intern Med. (2020) 173(11 Suppl):S19–s28. doi: 10.7326/M19-3249
102. Bais B, Molenaar NM, Bijma HH, Hoogendijk WJG, Mulder CL, Luik AI, et al. Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: a systematic review and meta-analysis. J Affect Disord. (2020) 269:18–27. doi: 10.1016/j.jad.2020.03.014
103. Park TW, Larochelle MR, Saitz R, Wang N, Bernson D, Walley AY. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction. (2020) 115(5):924–32. doi: 10.1111/add.14886
104. Grigoriadis S, Graves L, Peer M, Mamisashvili L, Dennis C-L, Vigod SN, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. J Clin Psychiatry. (2019) 80(4):18r12412. doi: 10.4088/JCP.18r12412
105. Rementería JL, Bhatt K. Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr. (1977) 90(1):123–6. doi: 10.1016/S0022-3476(77)80785-3
106. Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol. (2008) 199(4):396. doi: 10.1016/j.ajog.2008.06.088
107. Voshaar RCO, Couvee JE, Van Balkom AJLM, Mulder PGH, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. (2006) 189:213–20. doi: 10.1192/bjp.189.3.213
108. Chang JC, Tarr JA, Holland CL, De Genna NM, Richardson GE, Rodrigues KL, et al. Beliefs and attitudes regarding prenatal marijuana use: perspectives of pregnant women who report use. Drug Alcohol Depend. (2019) 196:14–20. doi: 10.1016/j.drugalcdep.2018.11.028
109. Young-Wolff KC, Sarovar V, Tucker LY, Avalos LA, Alexeeff S, Conway A, et al. Trends in marijuana use among pregnant women with and without nausea and vomiting in pregnancy, 2009-2016. Drug Alcohol Depend. (2019) 196:66–70. doi: 10.1016/j.drugalcdep.2018.12.009
110. Carlier J, Huestis MA, Zaami S, Pichini S, Busardo FP. Monitoring perinatal exposure to cannabis and synthetic cannabinoids. Ther Drug Monit. (2020) 42(2):194–204. doi: 10.1097/FTD.0000000000000667
111. Cohen K, Weinstein A. The effects of cannabinoids on executive functions: evidence from Cannabis and synthetic cannabinoids-A systematic review. Brain Sci. (2018) 8(3):133. doi: 10.3390/brainsci8030040
112. Ryan SA, Ammerman SD, O'Connor ME, AAP Committee on Substance Use and Prevention, AAP Section on Breastfeeding. Marijuana use during pregnancy and breastfeeding: implications for neonatal and childhood outcomes. Pediatrics. (2018) 142(3):e20181889. doi: 10.1542/peds.2018-1889
113. Kondo KK, et al. Pharmacotherapy for the treatment of Cannabis use disorder: a systematic review. Ann Intern Med. (2020) 172(6):398–412. doi: 10.7326/M19-1105
114. Kondo KK, Morasco BJ, Nugent SM, Ayers CK, O'Neil ME, Freeman M, et al. Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations. J Gen Intern Med. (2020) 35(12):3635–43. doi: 10.1007/s11606-020-06115-3
115. Buresh M, Ratner J, Zgierska A, Gordin V, Alvanzo A. Managing acute pain in patients taking medication for opioid use disorder: a rapid review. J Gen Intern Med. (2020) 35(Suppl 3):945–53. doi: 10.1007/s11606-020-06256-5
116. Veazie S, Mackey K, Peterson K, Bourne D. National partnership for maternal safety: consensus bundle on obstetric care for women with opioid use disorder. Obstet Gynecol. (2019) 134(2):365–75. doi: 10.1097/AOG.0000000000003381
117. Krans EE, Campopiano M, Cleveland L, Goodman D, Kilday D, Kendig SJD, et al. Care for pregnant and postpartum people with substance use disorder (2021). Available at: https://saferbirth.org/psbs/care-for-pregnant-and-postpartum-people-with-substance-use-disorder/ (Accessed September 15, 2022).
118. Association of women’s health, obstetric and neonatal nurses. Breastfeeding and the use of human milk. Pediatrics. (2012) 129(3):e827–41. doi: 10.1542/peds.2011-3552
119. Grywacheski V, et al. Opioid and Cannabis use during pregnancy and breastfeeding in relation to sociodemographics and mental health status: a descriptive study. J Obstet Gynaecol Can. (2021) 43(3):329–36. doi: 10.1016/j.jogc.2020.09.017
120. Grywacheski V, Ali J, Baker MM, Gheorghe M, Wong SL, Orpana HM. Test or talk: empiric bias and epistemic injustice. Obstet Gynecol. (2022) 140(2):150–2. doi: 10.1097/AOG.0000000000004884
121. Benitz WE, et al. Hospital stay for healthy term newborn infants. Pediatrics. (2015) 135(5):948–53. doi: 10.1542/peds.2015-0699
122. Benitz WE, Aucott S, Benitz WE, Cummings JJ, Eichenwald EC, Goldsmith J, et al. Standardizing the clinical definition of opioid withdrawal in the neonate. J Pediatr. (2022) 243:33–9. doi: 10.1016/j.jpeds.2021.12.021
123. Jilani SM, Jones HE, Grossman M, Jansson LM, Terplan M, Faherty LJ, et al. Opposition to criminalization of individuals during pregnancy and the postpartum period (2020).
124. Suomi A, Bolton A, Pasalich D. The prevalence of post-traumatic stress disorder in birth parents in child protection services: systematic review and meta-analysis. Trauma Violence Abuse. (2021) 24(2):1032–46. doi: 10.1177/15248380211048444
125. Sangoi L. Whatever they do, I'm her comfort, I'm her protector. How the foster system has become ground zero for the US drug war. Movement for family power (2020).
126. Meinhofer A, Angleró-Díaz Y. Trends in foster care entry among children removed from their homes because of parental drug use, 2000 to 2017. JAMA Pediatr. (2019) 173(9):881–3. doi: 10.1001/jamapediatrics.2019.1738
127. Admon LK, Zivin K, Kozhimannil KB. Perinatal insurance coverage and behavioural health-related maternal mortality. Int Rev Psychiatry. (2021) 33(6):553–6. doi: 10.1080/09540261.2021.1903843
128. MacDorman MF, et al. Causes contributing to the excess maternal mortality risk for women 35 and over, United States, 2016-2017. PLoS One. (2021) 16(6):e0253920. doi: 10.1371/journal.pone.0253920
129. MacDorman MF, Thorma M, Declercq E, Howell EA. Early lessons from maternal mortality review committees on drug-related deaths-time for obstetrical providers to take the lead in addressing addiction. Am J Obstet Gynecol MFM. (2020) 2(4):100177. doi: 10.1016/j.ajogmf.2020.100177
130. Smid MC, Schauberger CW, Terplan M, Wright TE. Recent increases in the U.S. maternal mortality rate: disentangling trends from measurement issues. Obstet Gynecol. (2016) 128(3):447–55. doi: 10.1097/AOG.0000000000001556
131. Grigoriadis S, et al. Perinatal suicide in Ontario, Canada: a 15-year population-based study. Can Med Assoc J. (2017) 189(34):E1085–e1092. doi: 10.1503/cmaj.170088
132. Grigoriadis S, Wilton AE, Kurdyak PA, Rhodes AE, VonderPorten EH, Levitt A, et al. Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality disorder. Addiction. (2017) 112(7):1250–9. doi: 10.1111/add.13788
133. Forray A, Yonkers KA. The collision of mental health, substance use disorder, and suicide. Obstet Gynecol. (2021) 137(6):1083–90. doi: 10.1097/AOG.0000000000004391
134. American College of Obstetricians and Gynecologists. Committee opinion no. 757: screening for perinatal depression. Obstet Gynecol. (2018) 132(5):e208–12. doi: 10.1097/AOG.0000000000002927
135. ACOG Committee opinion No. 736 summary: optimizing postpartum care. Obstet Gynecol. (2018) 131(5):949–51. doi: 10.1097/AOG.0000000000002628
136. Martino SC, et al. Exploring the link between substance use and abortion: the roles of unconventionality and unplanned pregnancy. Perspect Sex Reprod Health. (2006) 38(2):66–75. doi: 10.1363/3806606
137. Martino SC, Collins RL, Ellickson PL, Klein DJ. The prevalence of unplanned pregnancy and associated factors in britain: findings from the third national survey of sexual attitudes and lifestyles (natsal-3). Lancet. (2013) 382(9907):1807–16. doi: 10.1016/S0140-6736(13)62071-1
138. Wellings K, Jones KG, Mercer CH, Tanton C, Clifton S, Datta J, et al. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. (2011) 40(2):199–202. doi: 10.1016/j.jsat.2010.08.011
139. Heil SH, Jones HE, Arria A, Kaltenbacj K, Coyle M, Fischer G, et al. Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review. Prev Med. (2015) 80:23–31. doi: 10.1016/j.ypmed.2015.04.008
140. Terplan M, Hand DJ, Hutchinson M, Salisbury-Afshar E, Heil SH. Factors associated with contraceptive use among postpartum women with substance use disorder. Sex Reprod Healthc. (2022) 33:100764. doi: 10.1016/j.srhc.2022.100764
141. Shelton D, Ramage M, Hughes P, Tak C. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med. (2017) 166(11):775–82. doi: 10.7326/M16-2350
142. Ly KN, Jiles RB, Teshale EH, Foster MA, Pesano RL, Holmberg SD. Routine hepatitis C virus screening in pregnant individuals.
143. Faherty LJ, et al. Association between punitive policies and neonatal abstinence syndrome among medicaid-insured infants in complex policy environments. Addiction. (2022) 117(1):162–71. doi: 10.1111/add.15602
144. Faherty LJ, Heins S, Kranz AM, Patrick SW. Forty years of state alcohol and pregnancy policies in the USA: best practices for public health or efforts to restrict women's reproductive rights? Alcohol Alcohol. (2017) 52(6):715–21. doi: 10.1093/alcalc/agx047
145. Roberts SCM, Thomas S, Treffers R, Drabble L. Association between state-level criminal justice-focused prenatal substance use policies in the US and substance use-related foster care admissions and family reunification. JAMA Pediatr. (2020) 174(8):782–8. doi: 10.1001/jamapediatrics.2020.1027
Keywords: addiction, pregnancy, parenting, disparities, stigma
Citation: Barber CM and Terplan M (2023) Principles of care for pregnant and parenting people with substance use disorder: the obstetrician gynecologist perspective. Front. Pediatr. 11:1045745. doi: 10.3389/fped.2023.1045745
Received: 16 September 2022; Accepted: 17 April 2023;
Published: 24 May 2023.
Edited by:
Loretta Finnegan, Finnegan Consulting, LLC, United StatesReviewed by:
Alison Sally Poulton, The University of Sydney, AustraliaJennifer McKinney, Baylor College of Medicine, United States
© 2023 Terplan and Barber. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mishka Terplan bXRlcnBsYW5AZnJpZW5kc3Jlc2VhcmNoLm9yZw==